CAR T-cell Therapy Articles

CAR T-Cell Therapy, Checkpoint Inhibitors Making Waves Across Hematologic Malignancies
Anas Younes, MD, discusses the current and future state of CAR T-cell therapies and immune checkpoint inhibitors in the landscape of hematologic malignancies.
CAR T-Cell Payment Codes Don't Address True Cost
CMS's initial payment codes for CAR T-cell therapies are opposed by the medical community on the basis that they would be cumbersome to implement and wouldn't reflect the full amount of care delivered to each patient.
Selective T-Cell Depletion Improves Engraftment, Reduces GVHD in Pediatric/AYA Leukemia
Eliminating T cells carrying alpha and beta chains of the T-cell receptor reduced the risk for graft-versus-host-disease while producing "excellent" engraftment kinetics for young patients with acute leukemia who underwent hematopoietic stem cell transplant.
Memory-Related Genes May Overcome Resistance to CAR T-Cell Therapy in CLL
Results from a recent study may show why some patients with chronic lymphocytic leukemia are resistant to tisagenlecleucel, while potentially offering a pathway to enhance patient response.
FDA Approves Tisagenlecleucel for Large B-Cell Lymphoma
The FDA has approved tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma—after 2 or more lines of systemic therapy.
Expert Covers Burgeoning Role of CAR T-Cell Therapy in Myeloma
Maung Myo Htut, MD, discusses the use of CAR T-cell therapy in multiple myeloma and the potential infusion of immunotherapy into treatment.
FT819 Derives Renewable, Reproducible Process of CAR T-Cell Therapy
An off-the-shelf, dual-targeted chimeric antigen receptor T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies. 
Novel Agents, CAR T Cells Reinvigorate ALL Landscape
Jae H. Park, MD, discusses the impact of agents such as blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel on the treatment of acute lymphoblastic leukemia. 
Brentjens Highlights BCMA, Next Steps With CAR T-Cell Therapy
Renier J. Brentjens, MD, PhD, discusses the emergence of BCMA as a target for CAR T-cell therapy and other next steps for the field.
T-Cell Fuel Source, Chemotherapy Exposure Reduce Potential to Develop CAR-T Therapy
Both prior chemotherapy and a dependence on glycolysis appear to reduce the potential to develop T cells into chimeric antigen receptor T-cell therapy.
Publication Bottom Border
Border Publication